Form 4 Filing for AbCellera Biologics Inc. - Seely Lynn

Seely Lynn, a director at AbCellera Biologics Inc. (ABCL), acquired 152,207 share options on July 1, 2026. The options have an exercise price of $7.85 and expire on July 1, 2036. These options vest in three equal annual installments starting July 1, 2027, contingent upon continued service to the company. The filing indicates these are direct holdings, and Ms. Lynn now holds 152,207 shares post-transaction. This transaction is reported on Form 4.